{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:06Z","timestamp":1793726046247,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10067-025-07455-3","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:44:50Z","timestamp":1746009890000},"page":"2487-2500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low-dose IL-2 restores Tfh\/Tfr imbalance and modulates B cell subset distribution in the pre-arthritis phase of the collagen-induced arthritis model"],"prefix":"10.1007","volume":"44","author":[{"given":"Rui","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0817-7946","authenticated-orcid":false,"given":"Caihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"10","key":"7455_CR1","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K (2022) Global epidemiology of rheumatoid arthritis[J]. Nat Rev Rheumatol 18(10):591\u2013602","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"7455_CR2","doi-asserted-by":"publisher","first-page":"102797","DOI":"10.1016\/j.autrev.2021.102797","volume":"20","author":"N Petrovska","year":"2021","unstructured":"Petrovska N, Prajzlerova K, Vencovsky J, Senolt L, Filkova M (2021) The pre-clinical phase of rheumatoid arthritis: from risk factors to prevention of arthritis[J]. Autoimmun Rev 20(5):102\u2013797","journal-title":"Autoimmun Rev"},{"issue":"4","key":"7455_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3899\/jrheum.2023-0334","volume":"51","author":"LJ O\u2019Neil","year":"2024","unstructured":"O\u2019Neil LJ, Alpizar-Rodriguez D, Deane KD (2024) Rheumatoid arthritis: the continuum of disease and strategies for prediction, early intervention and prevention[J]. J Rheumatol 51(4):337\u2013349","journal-title":"J Rheumatol"},{"issue":"1","key":"7455_CR4","doi-asserted-by":"publisher","first-page":"103217","DOI":"10.1016\/j.autrev.2022.103217","volume":"22","author":"G Frazzei","year":"2023","unstructured":"Frazzei G, Musters A, de Vries N, Tas SW, van Vollenhoven RF (2023) Prevention of rheumatoid arthritis: a systematic literature review of preventive strategies in at-risk individuals[J]. Autoimmun Rev 22(1):103\u2013217","journal-title":"Autoimmun Rev"},{"issue":"13","key":"7455_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review[J]. JAMA 320(13):1360\u20131372","journal-title":"JAMA"},{"issue":"3","key":"7455_CR6","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.4049\/jimmunol.165.3.1557","volume":"165","author":"S Thornton","year":"2000","unstructured":"Thornton S, Boivin GP, Kim KN, Finkelman FD, Hirsch R (2000) Heterogeneous effects of IL-2 on collagen-induced arthritis[J]. J Immunol (Baltimore, Md\u202f: 1950) 165(3):1557\u20131563","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"12","key":"7455_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","volume":"17","author":"AGA Kolios","year":"2021","unstructured":"Kolios AGA, Tsokos GC, Klatzmann D (2021) Interleukin-2 and regulatory T cells in rheumatic diseases[J]. Nat Rev Rheumatol 17(12):749\u2013766","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"7455_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, Ri C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D (2019) Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial[J]. Ann Rheum Dis 78(2):209\u2013217","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7455_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z (2016) Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med 22(9):991\u2013993","journal-title":"Nat Med"},{"issue":"1","key":"7455_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","volume":"23","author":"M Miao","year":"2021","unstructured":"Miao M, Xiao X, Tian J, Zhufeng Y, Feng R, Zhang R, Chen J, Zhang X, Huang B, Jin Y, Sun X, He J, Li Z (2021) Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study[J]. Arthritis Res Ther 23(1):167","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"7455_CR11","doi-asserted-by":"publisher","first-page":"e1293","DOI":"10.1002\/cti2.1293","volume":"10","author":"K Liang","year":"2021","unstructured":"Liang K, He J, Wei Y, Zeng Q, Gong D, Qin J, Ding H, Chen Z, Zhou P, Niu P, Chen Q, Ding C, Lu L, Chen XX, Li Z, Shen N, Yu D, Deng J (2021) Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr\/Tfh ratio in lupus[J]. Clinical & translational immunology 10(6):e1293","journal-title":"Clinical & translational immunology"},{"issue":"2","key":"7455_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41419-019-1315-9","volume":"10","author":"J Yang","year":"2019","unstructured":"Yang J, Yang X, Yang J, Li M (2019) Baicalin ameliorates lupus autoimmunity by inhibiting differentiation of Tfh cells and inducing expansion of Tfr cells[J]. Cell Death Dis 10(2):140","journal-title":"Cell Death Dis"},{"issue":"7","key":"7455_CR13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/nprot.2007.258","volume":"2","author":"MC Fantini","year":"2007","unstructured":"Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C (2007) In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells[J]. Nat Protoc 2(7):1789\u20131794","journal-title":"Nat Protoc"},{"key":"7455_CR14","doi-asserted-by":"publisher","first-page":"6243019","DOI":"10.1155\/2020\/6243019","volume":"2020","author":"L He","year":"2020","unstructured":"He L, Shu X, Liu X, Ge Y, Li S, Lu X, Wang G (2020) Soluble IL-2 receptor in dermatomyositis: its associations with skin ulcers and disease activity[J]. Mediators Inflamm 2020:6243019","journal-title":"Mediators Inflamm"},{"issue":"8","key":"7455_CR15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","volume":"96","author":"M Lin","year":"2017","unstructured":"Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M, Mattman A, Schneider M, Chen LYC (2017) Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review[J]. Ann Hematol 96(8):1241\u20131251","journal-title":"Ann Hematol"},{"key":"7455_CR16","doi-asserted-by":"publisher","first-page":"938556","DOI":"10.3389\/fimmu.2022.938556","volume":"13","author":"D Long","year":"2022","unstructured":"Long D, Yu S, Zhang L, Guo Y, Xu S, Rao Y, Huang Z, Luo Q, Li J (2022) Increased sIL-2Ralpha leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2[J]. Front Immunol 13:938\u2013556","journal-title":"Front Immunol"},{"issue":"10429","key":"7455_CR17","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D\u2019Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT, APIPPRA study investigators (2024) Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial[J]. Lancet 403(10429):838\u2013849","journal-title":"Lancet"},{"issue":"10429","key":"7455_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber AJ, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler DM, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester GR, Karberg K, Strunk J, Canete JD, Senolt L, Filkova M, Naredo E, Largo R, Kronke G, D\u2019Agostino MA, Ostergaard M, Schett G (2024) Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial[J]. Lancet 403(10429):850\u2013859","journal-title":"Lancet"},{"issue":"2","key":"7455_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/art.41417","volume":"73","author":"KD Deane","year":"2021","unstructured":"Deane KD, Holers VM (2021) Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift[J]. Arthritis Rheumatol 73(2):181\u2013193","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"7455_CR20","doi-asserted-by":"publisher","first-page":"102645","DOI":"10.1016\/j.autrev.2020.102645","volume":"19","author":"R Wu","year":"2020","unstructured":"Wu R, Li N, Zhao X, Ding T, Xue H, Gao C, Li X, Wang C (2020) Low-dose interleukin-2: biology and therapeutic prospects in rheumatoid arthritis[J]. Autoimmun Rev 19(10):102645.","journal-title":"Autoimmun Rev"},{"key":"7455_CR21","doi-asserted-by":"publisher","first-page":"947341","DOI":"10.3389\/fimmu.2022.947341","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang SX, Chang JS, Cheng T, Jiang XJ, Su QY, Zhang JQ, Luo J, Li XF (2022) Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial[J]. Front Immunol 13:947341.","journal-title":"Front Immunol"},{"issue":"2","key":"7455_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/annrheumdis-2016-209830","volume":"76","author":"JS Dekkers","year":"2017","unstructured":"Dekkers JS, Schoones JW, Huizinga TW, Toes RE, van der Helm-van Mil AH (2017) Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis[J]. Ann Rheum Dis 76(2):458\u2013467","journal-title":"Ann Rheum Dis"},{"key":"7455_CR23","doi-asserted-by":"publisher","first-page":"1759720X2110113","DOI":"10.1177\/1759720X211011370","volume":"13","author":"SX Zhang","year":"2021","unstructured":"Zhang SX, Wang J, Wang CH, Jia RH, Yan M, Hu FY, Liu GY, Liu XY, Luo J, Gao C, Li XF (2021) Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis 13:1759720X211011370","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"7455_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/art.41457","volume":"73","author":"H Hao","year":"2021","unstructured":"Hao H, Nakayamada S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, Zhang M, Zhang T, Kanda Satoh Y, Shan Y, Otsuka T, Tanaka Y (2021) Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus[J]. Arthritis Rheumatol 73(1):132\u2013142","journal-title":"Arthritis Rheumatol"},{"key":"7455_CR25","doi-asserted-by":"publisher","first-page":"891925","DOI":"10.3389\/fimmu.2022.891925","volume":"13","author":"Y Meguri","year":"2022","unstructured":"Meguri Y, Asano T, Yoshioka T, Iwamoto M, Ikegawa S, Sugiura H, Kishi Y, Nakamura M, Sando Y, Kondo T, Sumii Y, Maeda Y, Matsuoka KI (2022) Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation[J]. Front Immunol 13:891\u2013925","journal-title":"Front Immunol"},{"issue":"1","key":"7455_CR26","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41467-023-37424-w","volume":"14","author":"A Inaba","year":"2023","unstructured":"Inaba A, Tuong ZK, Zhao TX, Stewart AP, Mathews R, Truman L, Sriranjan R, Kennet J, Saeb-Parsy K, Wicker L, Waldron-Lynch F, Cheriyan J, Todd JA, Mallat Z, Clatworthy MR (2023) Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells[J]. Nat Commun 14(1):2071","journal-title":"Nat Commun"},{"key":"7455_CR27","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","volume":"13","author":"M Lensing","year":"2022","unstructured":"Lensing M, Jabbari A (2022) An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata[J]. Front Immunol 13:955035","journal-title":"Front Immunol"},{"issue":"7","key":"7455_CR28","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.4049\/jimmunol.171.7.3435","volume":"171","author":"A Antov","year":"2003","unstructured":"Antov A, Yang L, Vig M, Baltimore D, Van Parijs L (2003) Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance[J]. J Immunol (Baltimore, Md\u202f: 1950) 171(7):3435\u20133441","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"5","key":"7455_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1182\/blood-2006-02-004747","volume":"108","author":"E Zorn","year":"2006","unstructured":"Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo[J]. Blood 108(5):1571\u20131579","journal-title":"Blood"},{"issue":"4","key":"7455_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S (2014) T follicular helper cell differentiation, function, and roles in disease[J]. Immunity 41(4):529\u2013542","journal-title":"Immunity"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07455-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07455-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07455-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:20:59Z","timestamp":1749129659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07455-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7455"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07455-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the second hospital of Shanxi medical university approved all animal experiments procedures (approval code DW2023037).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}